LNSR - NASDAQ
LENSAR, Inc.
$5.74
-2.0%LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
At a Glance
Live SnapshotLENSAR, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Strong gross margins indicate healthy pricing and efficient production or service delivery.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
LENSAR, Inc. Income Statement
LNSR • NASDAQ
| LENSAR, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
58.4M | 53.5M | 42.2M | 35.4M | 34.5M | 26.4M | 30.5M | 24.4M | |
GROSS PROFIT | ||||||||
(31.3M) | (27.6M) | (21.1M) | (15.4M) | (16.6M) | (12.3M) | (17.3M) | (14.8M) | |
27.1M | 25.9M | 21.1M | 20M | 17.8M | 14.1M | 13.2M | 9.6M | |
OPERATING INCOME | ||||||||
(51.7M) | (36.5M) | (33.3M) | (40.1M) | (37.5M) | (32.6M) | (25.9M) | (18.9M) | |
(45.2M) | (26.5M) | (26.1M) | (27.2M) | (23.9M) | (23.8M) | (17.1M) | (16.1M) | |
(5.6M) | (5.3M) | (6.1M) | (11.8M) | (12.4M) | (7.6M) | (7.6M) | (2.8M) | |
-24.6M | -10.7M | -12.2M | -20.2M | -19.7M | -18.5M | -12.7M | -9.3M | |
PRE-TAX INCOME | ||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (1.3M) | (2M) | (0.0) | |
91K | 103K | 85K | 17K | 34K | -1.3M | -2M | 0.0 | |
(921K) | (4.7M) | (1.1M) | (1.1M) | (1.2M) | (1.3M) | (1.2M) | (0.0) | |
-9.7M | -20.7M | -2.2M | 263K | 51K | -1.3M | -1.9M | -3.3M | |
-34.3M | -31.4M | -14.4M | -19.9M | -19.6M | -19.8M | -14.7M | -12.6M | |
NET INCOME | ||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (2.1M) | (20K) | |
-34.3M | -31.4M | -14.4M | -19.9M | -19.6M | -19.8M | -14.7M | -12.6M |
SEC Filings
LNSR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 25, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 08, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 08, 2026 | May 08, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 15, 2026 | April 10, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 16, 2026 | 2026 | |
8-K/A 8-K/A 2026 (Amended) N/A | March 13, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 |
Related Guides
Continue your LNSR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.